Navigation Links
Moffitt Cancer Center study validates activity of rare genetic variant in glioma
Date:7/2/2012

Researchers at Moffitt Cancer Center working with colleagues at three other institutions have validated a link between a rare genetic variant and the risk of glioma, the most common and lethal type of brain tumor. The validation study also uncovered an association between the same rare genetic variant and improved rates of survival for patients with glioma.

The study, the first to confirm a rare susceptibility variant in glioma, appeared in a recent issue of the Journal of Medical Genetics, a journal published by the British Medical Association.

"Glioma is a poorly understood cancer with high morbidity and devastating outcomes," said study lead author Kathleen M. Egan, Sc.D., interim program leader of Cancer Epidemiology and vice chair of the Department of Cancer Epidemiology. "However, the discovery of the association of the TP53 genetic variant rs78378222 with glioma provides new insights into these tumors and offers better prospects for identifying people at risk."

According to the authors, their study "genotyped' the single nucleotide polymorphism (SNP, or "snip") rs78378222 in TP53, an important tumor suppressor gene. The researchers said the SNP disrupts the TP53 signal and, because of its activity, has been linked to a variety of cancers. This study linked the presence of the rare form of rs78378222 to deadly glioma.

The researchers conducted a large, clinic-based, case-control study of individuals age 18 and older with a recent glioma diagnosis. A total of 566 glioma cases and 603 controls were genotyped for the rs78378222 variant.

Study results reveal that the odds of developing glioma were increased 3.5 times among the rare variant allele carriers. However, when researchers examined the impact of rs78378222 on survival, they found an approximately 50 percent reduction in death rates for those who were variant allele carriers.

"That the variant increased survival chances was an unexpected finding," Egan said. "It is tempting to speculate that the presence of the risk allele could direct tumor development into a less aggressive path."

The researchers concluded that their study results "may shed light on the etiology and progression of these tumors."

In addition to researchers from Moffitt, researchers from The University of Alabama at Birmingham, Emory School of Medicine and Vanderbilt University participated in the study and co-authored the paper.


'/>"/>

Contact: Patty Kim
patty.kim@moffitt.org
813-745-7322
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
2. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
3. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
4. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
5. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
6. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
7. Moffitt Cancer Center researchers develop and test new anti-cancer vaccine
8. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
9. Researchers creating designer lymph nodes based on Moffitts Total Cancer Care initiative
10. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
11. Moffitt researcher publishes book on nutritional management of cancer treatment effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man who ... the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at the ... and at 19 years of age, he joined the Navy and got married right out ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: ... published author, Sara Seymour, who lives in Lafayette, Indiana where she works in a ... iced coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book ...
(Date:1/20/2017)... ... ... Land of More and More”: a brilliant story for children and adults alike ... achievable answer. “The Land of More and More” is the creation of published author, ... where he works with the children’s ministry department. , Michael says that he ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Learning Management System: an On-demand E-learning system for Clinical and Regulatory education ... that is based on Aerolib`s successful education methodology of Disease Specific Documentation ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Stealth BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical ... new additions to its senior leadership team: W. ... Daniel Geffken as interim Chief Financial Officer. ... Pharm.D. has been promoted to Chief Clinical Development Officer. ... and Daniel to our management team, as both will ...
(Date:1/19/2017)... Accuray Incorporated (Nasdaq: ARAY ) ... to set the bar for excellence in customer satisfaction. ... satisfaction rating among radiation treatment delivery systems in the ... Intelligence Briefing™. The most recent ratings trend also shows ... peers for 11 of the past 12 quarters. ...
(Date:1/19/2017)... Fla. , Jan. 19, 2017  Sensus ... medical device company specializing in the treatment of ... as keloids, with superficial radiation therapy, today announced ... full year 2016 financial results on Thursday, February 2, ... Company will hold a conference call with the ...
Breaking Medicine Technology: